Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations
The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Abstract
With the correct selection of drug and patient, the calcium antagonists as a group can be remarkably effective at relatively low cost of serious side effects. Almost all side effects are dose related. Minor side effects include those caused by vasodilation (flushing and headaches), constipation (verapamil), and ankle edema. Serious side effects are rare and result from improper use of these agents, as when intravenous verapamil (or diltiazem) is given to patients with sinus or atrioventricular nodal depression from drugs or disease, or nifedipine to patients with aortic stenosis. The potential of a marked negative inotropic effect is usually offset by afterload reduction, especially in the case of nifedipine which actually has the most marked negative inotropic effect. Yet caution is required when even calcium antagonists, especially verapamil, are given to patients with myocardial failure unless caused by hypertensive heart disease. Drug interactions of calcium antagonists occur with other cardiovascular agents such as alpha-adrenergic blockers, beta-adrenergic blockers, digoxin, quinidine, and disopyramide. The most marked interaction with digoxin is that with verapamil, which may raise digoxin levels by over 50%. Combination therapy of calcium antagonists with beta-blockers is increasingly common, and is probably safest in the case of dihydropyridines. Other combinations being explored are those with angiotensin-converting enzyme inhibitors and diuretics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, some pharmacological side effects may be more effectively managed with exercise interventions rather than adding further medications to the patient’s regimen, potentially initiating a harmful “prescription cascade” [[544], [545], [546], [547]].”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [544]
Citations
Cites
Diltiazem: A Review of its Pharmacological Properties and Therapeutic Efficacy
Chaffman, M., & Brogden, R. N. (1985) · Drugs · doi:10.2165/00003495-198529050-00001 · Cited by 373 · cited 1×
“Besides additive effects on nodal tissue and additive negative inotropic effects, diltiazem can displace propranolol from plasma binding sites thereby elevating free propranolol levels [ 69 ].”
BackgroundSorkin, E. M., Clissold, S. P., & Brogden, R. N. (1985) · Drugs · doi:10.2165/00003495-198530030-00002 · Cited by 355 · cited 1×
“Nifedipine data from [3], [15], [16], [99], and [100]. See also [ 101 ].”
BackgroundTorsade De Pointes, an atypical ventricular tachycardia.
Krikler, D. M., & Curry, P. V. (1976) · Heart · doi:10.1136/hrt.38.2.117 · Cited by 344 · cited 1×
“Such side effects have not been reported with the three prototypical calcium antagonists but only with prenylamine, lidoflazine, and bepridil which may all prolong the Q-T interval with potential for precipitation of atypical ventricular tachycardia [45].”
BackgroundHemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man.
Packer, M., Meller, J., Medina, N., Yushak, M., Smith, H., Holt, J., Guererro, J., Todd, G. D., McAllister, R. G., & Gorlin, R. (1982) · Circulation · doi:10.1161/01.cir.65.4.660 · Cited by 332 · cited 1×
“verapamil [56] can reduce contractility [56], increase”
Calcium Antagonists and Cardiovascular Disease
McGoon, M. D. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60308-5 · Cited by 232
Nifedipine in hypertensive emergencies.
Bertel, O., Conen, D., Radü, E. W., Müller, J., Lang, C., & Dubach, U. C. (1983) · BMJ · doi:10.1136/bmj.286.6358.19 · Cited by 222
Roth, A., Harrison, E., Mitani, G., Cohen, J., Rahimtoola, S. H., & Elkayam, U. (1986) · Circulation · doi:10.1161/01.cir.73.2.316 · Cited by 196 · cited 2×
“Diltiazem 360 mg daily given instead of digoxin caused side effects in 9 of 12 patients (75%) with atrial fibrillation; 11 of these patients had mitral valve disease [38].”
BackgroundLynch, P., Dargie, H., Krikler, S., & Krikler, D. (1980) · BMJ · doi:10.1136/bmj.281.6234.184 · Cited by 191
Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan.
Kimura, E., & Kishida, H. (1981) · Circulation · doi:10.1161/01.cir.63.4.844 · Cited by 190 · cited 1×
“In a small open series [74], nifedipine plus diltiazem appears to be effective in all”
BackgroundDifferential cardiovascular effects of calcium channel blocking agents: Potential mechanisms
Millard, R. W., Lathrop, D. A., Grupp, G., Ashraf, M., Grupp, I. L., & Schwartz, A. (1982) · The American Journal of Cardiology · doi:10.1016/s0002-9149(82)80002-7 · Cited by 187 · cited 1×
“dipine may be considerably more powerful than verapamil or diltiazem in decreasing vagal tone [61],”
Background
Research works printed but not linked: 11
- Fleckenstein A. Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In: Harris P, Opie LH, eds. Calcium and the Heart. London: Academic Press, 1971;135?188.
- Opie LH, Singh BN. Calcium channel antagonists (slow channel blockers). In: Opie LH, ed. Drugs for the Heart Second Expanded Edition. Orlando, Florida: Grune & Stratton, 1987;34?53
- Norris RJ, Brooks SG. Pharmacokinetics of a sustained release formulation of verapamil in young and elderly adults. In: Raftery EB, ed. Verapamil SR. Once-daily Calcium Blockade in Angina and Hypertension. Langhorne: ADIS Press International, 1987;38?46.
- Leisten L, Kuhlmann J, Ebner F. Side effects and pharmacodynamic interactions. In: Krebs R, ed. Treatment of Cardiovascular Diseases by Adalat R (Nifedipine). Stuttgart-New York: Schattauer, 1986;270?314.
- Jee LD, Opie LH. Nifedipine for hypertension and angina pectoris: Interactions during combination therapy. In: Opie LH, ed. Calcium Antagonists and Cardiovascular Disease. New York: Raven Press, 1984;339?346.
- Bardet J, Baudet M, Rigaud M, et al. Diltiazem, a new calcium antagonist, versus propranolol in treatment of spontaneous angina pectoris (abstr). Am J Cardiol 1979; 43:416.
- Menasche S, Elkik F, Cocco G, et al. Synergistic antihypertensive effect of diltiazem combined with the alpha-adrenoceptor blocker alfuzosine (abstr). Ann NY Acad Sci (in press).
- Kleinbloesem CH, van Brummelen P, Sandberg THW, et al. Kinetic and haemodynamic interactions between nifedipine and propranolol in healthy subjects utilizing controlled rates of drug input. In: Kleinbloesem CH, ed. Nifedipine: Clinical Pharmacokinetics and Haemodynamic Effects. 's-Gravenhage: Drukkerij JH Pasmans BV, 1985;151?165.
- Kirch W. Dihydropyridine derivatives, influence on digoxin disposition and haemodynamics (abstr). Ann NY Acad Sci (in press).
- MacGregor GA: Hypertension. In: Krebs R, ed. Treatment of Cardiovascular Diseases by Adalat R (Nifedipine). Stuttgart: Schattauer, 1986; 231?258.
- Lahiri A, Dasgupta P, Rodrigues EA, et al. Acute drug withdrawal in patients with stable angina on long-term treatment with verapamil. In: Raftery EB, ed. Verapamil SR. Langhorne: ADIS Press International, 1987;18?29.
Cited by
Izquierdo, M., de Souto Barreto, P., Arai, H., Bischoff-Ferrari, H. A., Cadore, E. L., Cesari, M., Chen, L.-K., Coen, P. M., Courneya, K. S., Duque, G., et al. (2025) · The Journal of nutrition, health and aging · doi:10.1016/j.jnha.2024.100401 · Cited by 273
Cipriani, A., Saunders, K., Attenburrow, M.-J., Stefaniak, J., Panchal, P., Stockton, S., Lane, T. A., Tunbridge, E. M., Geddes, J. R., & Harrison, P. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.86 · Cited by 111
Ro 40–5967: A New Nondihydropyridine Calcium Antagonist
Clozel, J., Osterrieder, W., Kleinbloesem, C. H., Welker, H. A., Schläppi, B., Tudor, R., Hefti, F., Schmitt, R., & Eggers, H. (1991) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.1991.tb00539.x · Cited by 103
Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension
Pedrinelli, R., Dell’Omo, G., & Mariani, M. (2001) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001201 · Cited by 72
Stroke precipitated by moderate blood pressure reduction
Fischberg, G. M., Lozano, E., Rajamani, K., Ameriso, S., & Fisher, M. (2000) · Journal of Emergency Medicine · doi:10.1016/s0736-4679(00)00267-5 · Cited by 70
Pharmacological differences between calcium antagonists
Opie, L. H. (1997) · European Heart Journal · doi:10.1093/eurheartj/18.suppl_a.71 · Cited by 68
Self-citationAmlodipine, Enalapril, and Dependent Leg Edema in Essential Hypertension
Pedrinelli, R., Dell’Omo, G., Melillo, E., & Mariani, M. (2000) · Hypertension · doi:10.1161/01.hyp.35.2.621 · Cited by 63
Fogari, R., Malamani, G. D., Zoppi, A., Preti, P. S., Vanasia, A., Fogari, E., & Mugellini, A. (2000) · Current Therapeutic Research · doi:10.1016/s0011-393x(00)90012-2 · Cited by 57
Opie, L. H. (1996) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(96)80014-4 · Cited by 57
Self-citationDrug Interactions with Angiotensin Receptor Blockers: A Comparison with Other Antihypertensives
Unger, T., & Kaschina, E. (2003) · Drug Safety · doi:10.2165/00002018-200326100-00004 · Cited by 53
Mechanisms and repair strategies for white matter degeneration in CNS injury and diseases
Shahsavani, N., Kataria, H., & Karimi‐Abdolrezaee, S. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166117 · Cited by 45
Noll, G., & Lüscher, T. F. (1998) · Cardiology · doi:10.1159/000047274 · Cited by 42
Pedrinelli, R., Dell’Omo, G., Nuti, M., Menegato, A., Balbarini, A., & Mariani, M. (2003) · Journal of Hypertension · doi:10.1097/00004872-200310000-00026 · Cited by 41
Outpatient management of essential hypertension: a review based on the latest clinical guidelines
Moiz, A., Zolotarova, T., & Eisenberg, M. J. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2338242 · Cited by 39
“Furthermore, non-dihydropyridines should not be combined with beta-blockers because they can enhance the negative inotropic, chronotropic, and dro-motropic effects of beta-blockers [95].”
BackgroundIzquierdo, M., Ramírez‐Vélez, R., & Singh, M. F. (2025) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2025.100763 · Cited by 37
O’Brien, K. D., Zhao, X.-Q., Shavelle, D. M., Caulfield, M. T., Letterer, R. A., Kapadia, S. R., Probstfield, J. L., & Otto, C. M. (2004) · Journal of Investigative Medicine · doi:10.1177/108155890405200334 · Cited by 36
Absence of a Clinically Relevant Interaction Between Etanercept and Digoxin
Zhou, H., Parks, V., Patat, A. A., Coz, F. L., Simcoe, D. K., & Korth-Bradley, J. M. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004268050 · Cited by 36
“”(21) Several early clinically relevant interactions have been well documented between some cardiovascular drugs and digoxin, such as spironolactone-digoxin,(22,23) quinidine-digoxin,(24) and verapamil-digoxin.(25,26) These interactions were implicated by interfering the renal tubular secretion of digoxin.”
BackgroundSynthesis and biological evaluation of novel T-type Ca2+ channel blockers
Jung, H. K., Doddareddy, M. R., CHA, J. H., Rhim, H., Cho, Y. S., Koh, H. Y., Jung, B. Y., & Pae, A. N. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.06.011 · Cited by 36
Sandmann, S., Spitznagel, H., Chung, O., Xia, Q.-G., Illner, S., Jänichen, G., Rossius, B., Daemen, M. J. A. P., & Unger, T. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00087-x · Cited by 32
Drug-induced acute liver failure and gastrointestinal complications
Lat, I., Foster, D. R., & Erstad, B. L. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181de0db2 · Cited by 31
“Aluminum antacids 25% (141) Anticholinergics Up to 42% (142) Anticonvulsants 6% (141) Antihistamines (H1 antagonists) 27% (141) Antipsychotics 10% (141) Antispasmodics 21% (141) -adrenergic blockers 16% (141) Calcium channel blockers Diltiazem 25% (143) Verapamil 25–40% (143) Clonidine 1–10% (144) Disopyramide 11% (14…”
BackgroundPharmacology of the calcium antagonist mibefradil
Lüscher, T. F., Clozel, J., & Noll, G. (1997) · Journal of Hypertension · doi:10.1097/00004872-199715033-00003 · Cited by 31
Thakali, K. M., Kharade, S. V., Sonkusare, S. K., Rhee, S. W., Stimers, J. R., & Rusch, N. J. (2010) · Circulation Research · doi:10.1161/circresaha.109.206763 · Cited by 29
Ankle Oedema and Sympathetic Activation
Fogari, R. (2005) · Drugs · doi:10.2165/00003495-200565002-00004 · Cited by 29
“Approximately 15 years ago, Opie[1] reported that this adverse event occurred in 1–15% of patients.”
BackgroundInfluentialSandmann, S., Min, J. Y., Meissner, A., & Unger, T. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00180-7 · Cited by 24
DiBianco, R., Schoomaker, F. W., Singh, J. B., Awan, N. A., Bennett, T., Canosa, F. L., Kawanishi, D. T., Bamrah, V. S., Glasser, S. P., & Barry, W. H. (1992) · Clinical Cardiology · doi:10.1002/clc.4960150709 · Cited by 24
Richy, F. F., & Laurent, S. (2010) · Blood Pressure · doi:10.3109/08037051.2010.518670 · Cited by 22
Arrokhman, S., Luo, Y.-H., & Lin, P. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.115225 · Cited by 21
Argenziano, L., Izzo, R., Iovino, G. L., LUCA, N. D., Parrella, L., Morisco, C., & Trimarco, B. (1998) · Blood Pressure · doi:10.1080/080370598438546 · Cited by 20
Walker, J. M., Curry, P. V. L., Bailey, A., & Steare, S. E. (1996) · International Journal of Cardiology · doi:10.1016/0167-5273(95)02531-6 · Cited by 20
Aspects of quality of life on treatment with felodipine
Dimenäs, E., Wallander, M. ‐., Svärdsudd, K., & Wiklund, I. E. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00280068 · Cited by 20
Lee, M. J., Shin, T. J., Lee, J. E., Choo, H., Koh, H. Y., Chung, H. J., Pae, A. N., Lee, S. C., & Kim, H. J. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.018 · Cited by 19
“Compared with Ca2+ channel blockers specific for other subtypes, T-type Ca2+ channel blockers may have decreased incidence of side effects such as atrioventricular blockage and negative inotropism (Opie, 1988).”
Fogari, R., Zoppi, A., Mugellini, A., Maffioli, P., Lazzari, P., Monti, C. M., & Derosa, G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.580276 · Cited by 19
“Peripheral edema, particularly of lower extremity, develops in up to 15% of patients treated with dihydropyridine calcium channel blockers (CCBs) and is sometimes pronounced enough to lead to withdrawal of therapy [1-3].”
BackgroundZidek, W., Spieker, C., Knaup, G., Steindl, L., & Breuer, H.-W. M. (1995) · Clinical Therapeutics · doi:10.1016/0149-2918(95)80045-x · Cited by 19
Calcium Channel Blockers: Their Pharmacologic and Therapeutic Role in Hypertension
Weir, M. R. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707001-00002 · Cited by 16
Radial artery or saphenous vein for coronary artery bypass grafting
Audisio, K., Halbreiner, M. S., Chadow, D., & Gaudino, M. F. L. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.09.007 · Cited by 14
L- and T-type calcium channel blockade - the efficacy of the calcium channel antagonist mibefradil
Sandmann, S., & Unger, T. (1999) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 13
Gotanda, K., Yokoyama, H., Satoh, K., & Taira, N. (1989) · Cardiovascular Drugs and Therapy · doi:10.1007/bf01865509 · Cited by 13
“Nonvasoselective calcium antagonists such as verapamil and diltiazem have untoward effects in that they depress sinoatrial node activity and AV nodal conduction [28, 29 ].”
BackgroundManidipine: A different dihydropyridine
Rizos, C. V. (2011) · World Journal of Hypertension · doi:10.5494/wjh.v1.i1.3 · Cited by 11
T- and L-Type Ca2+-Channel Antagonists Reduce Contractility in Guinea Pig Cardiac Myocytes
Hoischen, S., Brixius, K., & Schwinger, R. H. G. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199808000-00022 · Cited by 11
Subedi, D., Kahlon, A. S., Gnanabakthan, N., & Dhillon, A. (2015) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.168053 · Cited by 10
Effects of felodipine versus nifedipine on exercise tolerance in stable angina pectoris
Ekelund, L. G., Ulvenstam, G., Walldius, G., & Åberg, A. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90929-6 · Cited by 10
Oliveto, A. H., Mancino, M. J., Sanders, N., Cargile, C. S., Guise, J. B., Bickel, W. K., & Gentry, W. B. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.03.007 · Cited by 8
“Dihydropyridines are more likely to produce side effects related to vasodilatation (Opie, 1988), while verapamil produces constipation (e.g., (Rosei et al., 1997; White et al., 2001)).”
BackgroundYoneyama, F., Yamada, H., Satoh, K., & Taira, N. (1990) · Cardiovascular Drugs and Therapy · doi:10.1007/bf02026494 · Cited by 7
“As verapamil and diltiazem, the currently available calcium antagonists for these purposes, do not discriminate between the SA and the AV node [6,7], supraventricular tachyarrhythmias that accompany depressed SA node activity, such as the sick sinus syndrome, are contraindications for intravenous therapy with these ca…”
BackgroundOstroumova, O. D., Shakhova, E. Y., & Kochetkov, A. I. (2020) · Russian Journal of Evidence-Based Gastroenterology · doi:10.17116/dokgastro2020901120 · Cited by 6
Potential Treatments for Refractory Vasospastic Angina
Ito, S., & Shimizu, Y. (2021) · Journal of Coronary Artery Disease · doi:10.7793/jcad.27.21-00012 · Cited by 6
Co-medications, pre-medication and common diseases in the elderly
Bruessel, T. (2003) · Best practice & research. Clinical anaesthesiology · doi:10.1016/s1521-6896(03)00009-0 · Cited by 5
Levy, B. P., Rosenberg, L., Colasante, D., & Deitch, M. W. (1993) · Clinical Drug Investigation · doi:10.1007/bf03259233 · Cited by 3
Dharmarajan, T. S., Widjaja, D., & Pitchumoni, C. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-30192-7_45 · Cited by 2
Batista, M. C., Plavnik, F. L., Kohlmann, N. E. B., Ortega, K. C., Mion, D., Pinho, C., da Rocha, J. C., Oigman, W., & Kohlmann, O. (1996) · Brazilian Journal of Nephrology · Cited by 1
Schindler, S. S. C. (2021) · Elsevier eBooks · doi:10.1016/b978-3-437-48781-1.00016-8 · Cited by 1
Efficacy and Safety of Calcium Antagonists as Antianginal Agents
Opie, L. H. (1994) · Developments in cardiovascular medicine · doi:10.1007/978-1-4615-2628-5_17
Self-citationDharmarajan, T. S., Widjaja, D., & Pitchumoni, C. S. (2020) · Springer eBooks · doi:10.1007/978-3-319-90761-1_45-1
Dharmarajan, T. S., Dharmarajan, T. S., Dharmarajan, T. S., Dharmarajan, T. S., Widjaja, D., Pitchumoni, C. S., Pitchumoni, C. S., & Pitchumoni, C. S. (2012) · Springer eBooks · doi:10.1007/978-1-4419-1623-5_34
Clinically Significant Drug-Drug Interactions
Churchwell, M. D., & Reinert, J. P. (2026) · Springer eBooks · doi:10.1007/978-3-032-21675-5_20
Metadata
- Authors
- Opie, L. H.
- Affiliations
- University of Cape Town (ZA)
- Corresponding author
- Opie, Lionel H.
- Venue
- Cardiovascular Drugs and Therapy
- Published
- 1988-07
- Volume
- 2
- Issue
- 2
- Pages
- 177-189
- ISSN
- 0920-3206 (ISSN-L)
- 1573-7241
- OpenAlex
- W1999013996
- Cited by
- 52
- References
- 99
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2021: 5 · 2020: 2 · 2016: 1 · 2015: 1 · 2013: 1 · 2012: 1
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cardiovascular Drugs and Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Keywords
- calcium channel blockers, verapamil, diltiazem, nifedipine, adverse drug reactions, contraindications, drug interactions, beta-blocker combination therapy, dihydropyridines, negative inotropic effect, myocardial failure, aortic stenosis, alpha-blockers, ACE inhibitors, diuretics, vasodilation
- MeSH terms
- Calcium Channel Blockers, Cardiovascular Diseases, Drug Interactions, Drug Therapy, Combination, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.